

**Listing 16.2.6.7**  
**Immunogenicity Results (Mucosal IgA)**

**Part B**

| Randomisation<br>Number | Group    | -----IgA ELISA Absorbance Data----- |       |       |        | -IgA ELISA Normalised Absorbance Data- |       |       |        |
|-------------------------|----------|-------------------------------------|-------|-------|--------|--|-------|-------|--------|
|                         |          | Day 1                               | Day 4 | Day 8 | Day 22 | Day 1                                  | Day 4 | Day 8 | Day 22 |
| B0011                   | Group B8 | 0.19                                | 0.16  | 0.38  | 0.24   | 0.22                                   | 0.18  | 0.42  | 0.27   |
| B0014                   | Group B3 | 0.16                                | 0.14  | 0.43  | 0.17   | 0.18                                   | 0.16  | 0.48  | 0.19   |
| B0015                   | Group B9 | 0.02                                | 0.05  | 0.08  | 0.10   | 0.03                                   | 0.06  | 0.09  | 0.11   |
| B0017                   | Group B7 | 0.38                                | 0.25  | 0.53  | 0.40   | 0.42                                   | 0.28  | 0.59  | 0.45   |
| B0018                   | Group B9 | 0.23                                | 0.23  | 0.44  | 0.20   | 0.25                                   | 0.26  | 0.49  | 0.22   |
| B0021                   | Group B7 | 0.28                                | 0.36  | 0.32  | 0.37   | 0.31                                   | 0.40  | 0.36  | 0.41   |
| B0023                   | Group B3 | 0.09                                | 0.16  | 0.40  | 0.27   | 0.10                                   | 0.18  | 0.45  | 0.30   |
| B0025                   | Group B8 | 0.25                                | 0.26  | 0.30  | 0.13   | 0.27                                   | 0.28  | 0.33  | 0.14   |
| B0026                   | Group B9 | 0.46                                | 0.29  | 0.27  | 0.60   | 0.50                                   | 0.32  | 0.29  | 0.65   |
| B0027                   | Group B3 | 0.37                                | 0.12  | 0.42  | 0.41   | 0.41                                   | 0.13  | 0.45  | 0.45   |
| B0030                   | Group B7 | 0.92                                | 0.49  | 0.45  | 0.65   | 1.04                                   | 0.55  | 0.50  | 0.74   |
| B0034                   | Group B8 | 0.38                                | 0.26  | 0.39  | 0.20   | 0.41                                   | 0.28  | 0.43  | 0.22   |
| B0035                   | Group B9 | 0.57                                | 0.32  | 0.49  | 0.52   | 0.62                                   | 0.35  | 0.54  | 0.57   |
| B0036                   | Group B7 | 0.18                                | 0.14  | 0.13  | 0.11   | 0.20                                   | 0.15  | 0.14  | 0.12   |
| B0038                   | Group B3 | 0.53                                | 0.45  | 0.51  | 0.51   | 0.60                                   | 0.51  | 0.58  | 0.58   |
| B0039                   | Group B7 | 0.41                                | 0.53  | 0.97  | 0.55   | 0.46                                   | 0.60  | 1.09  | 0.63   |
| B0040                   | Group B9 | 0.22                                | 0.22  | 0.20  | 0.09   | 0.24                                   | 0.23  | 0.22  | 0.09   |
| B0041                   | Group B3 | 0.49                                | 0.64  | 0.85  | 0.32   | 0.54                                   | 0.70  | 0.93  | 0.35   |

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

**Listing 16.2.6.7**  
**Immunogenicity Results (Mucosal IgA)**

**Part B**

| Randomisation<br>Number | Group    | -----IgA ELISA Absorbance Data----- |       |       |        | -IgA ELISA Normalised Absorbance Data- |       |       |        |
|-------------------------|----------|-------------------------------------|-------|-------|--------|--|-------|-------|--------|
|                         |          | Day 1                               | Day 4 | Day 8 | Day 22 | Day 1                                  | Day 4 | Day 8 | Day 22 |
| B0043                   | Group B8 | 0.22                                | 0.20  | 0.50  | 0.28   | 0.24                                   | 0.21  | 0.55  | 0.31   |
| B0046                   | Group B7 | 0.55                                | 0.34  | 0.55  | 0.42   | 0.61                                   | 0.37  | 0.60  | 0.45   |
| B0047                   | Group B9 | 0.38                                | 0.40  | 0.18  | 0.19   | 0.41                                   | 0.43  | 0.20  | 0.21   |
| B0050                   | Group B8 | 0.19                                | 0.30  | 0.44  | 0.44   | 0.20                                   | 0.33  | 0.48  | 0.48   |
| B0051                   | Group B3 | 0.20                                | 0.29  | 0.31  | 0.36   | 0.22                                   | 0.31  | 0.34  | 0.39   |
| B0055                   | Group B8 | 1.14                                | 0.78  | 0.94  | 0.65   | 1.24                                   | 0.85  | 1.03  | 0.71   |
| B0056                   | Group B3 | 0.14                                | 0.21  | 0.28  | 0.24   | 0.16                                   | 0.24  | 0.33  | 0.28   |
| B0058                   | Group B9 | 0.23                                | 0.07  | 0.59  | 0.25   | 0.26                                   | 0.07  | 0.67  | 0.28   |
| B0059                   | Group B7 | 0.41                                | 0.43  | 0.32  | 0.31   | 0.47                                   | 0.49  | 0.37  | 0.35   |
| B0060                   | Group B3 | 0.34                                | 0.59  | 1.04  | 0.66   | 0.39                                   | 0.68  | 1.18  | 0.75   |
| B0061                   | Group B8 | 0.15                                | 0.16  | 0.20  | 0.19   | 0.17                                   | 0.18  | 0.23  | 0.22   |
| B0063                   | Group B7 | 0.23                                | 0.38  | 0.16  | 0.21   | 0.26                                   | 0.44  | 0.19  | 0.24   |
| B0064                   | Group B9 | 1.43                                | 1.33  | 1.37  | 1.17   | 1.63                                   | 1.52  | 1.57  | 1.34   |
| B0067                   | Group B8 | 0.83                                | 0.29  | 0.33  | 0.21   | 0.90                                   | 0.31  | 0.35  | 0.22   |
| B0069                   | Group B7 | 0.61                                | 0.41  | 0.44  | 0.36   | 0.70                                   | 0.46  | 0.51  | 0.42   |
| B0070                   | Group B9 | 0.45                                | 0.28  | 0.66  | 0.40   | 0.49                                   | 0.30  | 0.70  | 0.43   |
| B0072                   | Group B3 | 0.47                                | 0.55  | 0.36  | 0.34   | 0.51                                   | 0.59  | 0.39  | 0.37   |
| B0074                   | Group B9 | 0.83                                | 0.63  | 0.77  | 0.48   | 0.89                                   | 0.68  | 0.83  | 0.52   |

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

**Listing 16.2.6.7**  
**Immunogenicity Results (Mucosal IgA)**

**Part B**

| Randomisation<br>Number | Group    | -----IgA ELISA Absorbance Data----- |       |       |        | -IgA ELISA Normalised Absorbance Data- |       |       |        |
|-------------------------|----------|-------------------------------------|-------|-------|--------|--|-------|-------|--------|
|                         |          | Day 1                               | Day 4 | Day 8 | Day 22 | Day 1                                  | Day 4 | Day 8 | Day 22 |
| B0075                   | Group B3 | 0.20                                | 0.35  | 0.71  | 0.34   | 0.21                                   | 0.38  | 0.76  | 0.37   |
| B0078                   | Group B8 | 0.22                                | 0.43  | 0.60  | 0.59   | 0.24                                   | 0.46  | 0.65  | 0.64   |
| B0082                   | Group B3 | 0.46                                |       | 0.57  | 0.35   | 0.48                                   |       | 0.59  | 0.36   |
| B0083                   | Group B8 | 0.45                                | 0.28  | 1.07  | 0.71   | 0.47                                   | 0.29  | 1.11  | 0.74   |
| B0086                   | Group B9 | 0.45                                | 0.54  | 0.43  | 0.29   | 0.48                                   | 0.58  | 0.46  | 0.32   |
| B0087                   | Group B7 | 0.37                                | 0.54  | 0.47  | 0.35   | 0.40                                   | 0.58  | 0.51  | 0.37   |
| B0088                   | Group B9 | 0.57                                | 0.40  | 1.20  | 0.44   | 0.65                                   | 0.46  | 1.36  | 0.49   |
| B0091                   | Group B8 | 0.30                                | 0.56  | 1.06  | 0.61   | 0.34                                   | 0.63  | 1.20  | 0.69   |
| B0093                   | Group B7 | 0.50                                | 0.64  | 0.33  | 0.45   | 0.57                                   | 0.72  | 0.37  | 0.51   |
| B0094                   | Group B3 | 0.10                                | 0.11  | 0.14  | 0.11   | 0.12                                   | 0.13  | 0.16  | 0.12   |
| B0095                   | Group B9 | 1.26                                | 0.35  | 0.37  | 0.32   | 1.36                                   | 0.37  | 0.40  | 0.35   |
| B0098                   | Group B7 | 0.73                                | 0.41  | 0.65  | 0.62   | 0.83                                   | 0.46  | 0.73  | 0.71   |
| B0100                   | Group B8 | 0.95                                | 0.63  | 0.76  | 0.85   | 1.07                                   | 0.71  | 0.86  | 0.96   |
| B0101                   | Group B3 | 0.66                                | 0.58  | 0.70  | 0.67   | 0.75                                   | 0.66  | 0.79  | 0.75   |
| B0102                   | Group B8 | 0.83                                | 0.97  | 0.74  | 0.80   | 0.91                                   | 1.06  | 0.81  | 0.88   |
| B0104                   | Group B3 | 0.19                                | 0.12  | 0.46  | 0.40   | 0.21                                   | 0.13  | 0.50  | 0.44   |
| B0105                   | Group B9 | 0.60                                | 0.37  | 0.67  | 0.52   | 0.66                                   | 0.40  | 0.73  | 0.57   |
| B0108                   | Group B7 | 0.86                                | 0.57  | 1.04  | 0.74   | 0.94                                   | 0.62  | 1.14  | 0.80   |

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

**Listing 16.2.6.7**  
**Immunogenicity Results (Mucosal IgA)**

**Part B**

| Randomisation<br>Number | Group    | -----IgA ELISA Absorbance Data----- |       |       |        | -IgA ELISA Normalised Absorbance Data- |       |       |        |
|-------------------------|----------|-------------------------------------|-------|-------|--------|--|-------|-------|--------|
|                         |          | Day 1                               | Day 4 | Day 8 | Day 22 | Day 1                                  | Day 4 | Day 8 | Day 22 |
| B0110                   | Group B3 | 0.87                                | 0.51  | 0.97  | 0.64   | 0.95                                   | 0.56  | 1.06  | 0.70   |
| B0111                   | Group B8 | 0.21                                | 0.10  | 0.34  | 0.29   | 0.23                                   | 0.11  | 0.37  | 0.32   |
| B0114                   | Group B7 | 0.79                                | 0.61  | 0.75  | 0.58   | 0.86                                   | 0.66  | 0.82  | 0.64   |
| B0115                   | Group B9 | 0.43                                | 0.31  | 0.63  | 0.42   | 0.49                                   | 0.36  | 0.72  | 0.48   |
| B0116                   | Group B7 | 0.64                                | 0.83  | 0.38  | 0.30   | 0.73                                   | 0.94  | 0.43  | 0.34   |
| B0117                   | Group B9 | 0.47                                | 0.31  | 0.30  | 0.55   | 0.54                                   | 0.35  | 0.35  | 0.62   |
| B0120                   | Group B3 | 0.14                                | 0.20  | 0.34  | 0.19   | 0.15                                   | 0.23  | 0.39  | 0.21   |
| B0121                   | Group B8 | 0.76                                | 0.57  | 0.79  | 0.64   | 0.79                                   | 0.59  | 0.82  | 0.67   |
| B0125                   | Group B7 | 0.19                                | 0.11  | 0.13  | 0.24   | 0.21                                   | 0.12  | 0.14  | 0.27   |
| B0126                   | Group B3 | 0.26                                | 0.25  | 0.79  | 0.57   | 0.29                                   | 0.29  | 0.90  | 0.65   |
| B0127                   | Group B9 | 0.21                                | 0.18  | 0.28  | 0.40   | 0.22                                   | 0.18  | 0.29  | 0.42   |
| B0129                   | Group B8 | 0.22                                | 0.18  | 0.34  | 0.28   | 0.23                                   | 0.20  | 0.37  | 0.30   |
| B0131                   | Group B8 | 0.37                                | 0.39  | 0.67  | 0.39   | 0.43                                   | 0.44  | 0.76  | 0.44   |
| B0134                   | Group B3 | 0.73                                | 0.77  | 0.50  | 0.76   | 0.73                                   | 0.77  | 0.51  | 0.77   |
| B0135                   | Group B7 | 0.17                                | 0.19  | 0.15  | 0.24   | 0.18                                   | 0.20  | 0.16  | 0.24   |
| B0136                   | Group B9 | 0.31                                | 0.25  | 0.37  | 0.25   | 0.32                                   | 0.25  | 0.37  | 0.25   |
| B0137                   | Group B8 | 0.39                                | 0.23  | 0.88  | 0.34   | 0.39                                   | 0.24  | 0.89  | 0.35   |
| B0138                   | Group B7 | 0.22                                | 0.18  | 0.30  | 0.22   | 0.22                                   | 0.18  | 0.30  | 0.22   |

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

**Listing 16.2.6.7**  
**Immunogenicity Results (Mucosal IgA)**

**Part B**

|               |          | -----IgA ELISA Absorbance Data----- |       |       |        | -IgA ELISA Normalised Absorbance Data- |       |       |        |
|---------------|----------|-------------------------------------|-------|-------|--------|--|-------|-------|--------|
| Randomisation |          |                                     |       |       |        |  |       |       |        |
| Number        | Group    | Day 1                               | Day 4 | Day 8 | Day 22 | Day 1                                  | Day 4 | Day 8 | Day 22 |
| B0140         | Group B9 | 0.55                                | 0.96  | 0.65  | 0.39   | 0.56                                   | 0.97  | 0.66  | 0.39   |
| B0141         | Group B3 | 0.45                                | 0.44  | 0.93  | 1.11   | 0.47                                   | 0.47  | 0.98  | 1.17   |
| B0145         | Group B3 | 0.45                                | 0.34  | 0.38  | 0.17   | 0.48                                   | 0.36  | 0.40  | 0.18   |
| B0146         | Group B7 | 0.51                                | 0.46  | 0.68  | 1.23   | 0.54                                   | 0.48  | 0.72  | 1.29   |
| B0147         | Group B9 | 0.23                                | 0.48  | 0.15  | 0.18   | 0.24                                   | 0.50  | 0.15  | 0.19   |
| B0149         | Group B8 | 0.40                                | 0.24  | 0.26  | 0.21   | 0.42                                   | 0.25  | 0.28  | 0.22   |
| B1019         | Group B8 | 0.44                                | 1.02  | 1.03  | 0.88   | 0.47                                   | 1.10  | 1.11  | 0.95   |
| B1080         | Group B7 | 0.59                                | 0.65  | 0.65  | 0.72   | 0.62                                   | 0.69  | 0.68  | 0.76   |

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)